Literature DB >> 21914071

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.

G Nkontchou1, M Ziol, M Aout, M Lhabadie, Y Baazia, A Mahmoudi, D Roulot, N Ganne-Carrie, V Grando-Lemaire, J-C Trinchet, E Gordien, E Vicaut, I Baghad, M Beaugrand.   

Abstract

Liver steatosis is a main histopathological feature of Hepatitis C (HCV) infection because of genotype 3. Steatosis and/or mechanisms underlying steatogenesis can contribute to hepatocarcinogenesis. The aim of this retrospective study was to assess the impact of infection with HCV genotype 3 on hepatocellular carcinoma (HCC) occurrence in patients with ongoing HCV cirrhosis. Three hundred and fifty-three consecutive patients (193 men, mean age 58 ± 13 years), with histologically proven HCV cirrhosis and persistent viral replication prospectively followed and screened for HCC between 1994 and 2007. Log-rank test and Cox model were used to compare the actuarial incidence of HCC between genotype subgroups. The patients infected with a genotype 3 (n = 25) as compared with those infected with other genotypes (n = 328) had a lower prothrombin activity [78 (interquartile range 60-85) vs 84 (71-195) %, P = 0.03] and higher rate of alcohol abuse (48%vs 29%, P = 0.046). During a median follow-up of 5.54 years [2.9-8.6], 11/25 patients (44%) and 87/328 patients (26%) with a genotype 3 and non-3 genotype, respectively, develop a HCC. HCC incidences were significantly different among the genotype subgroups (P = 0.001). The 5-year occurrence rate of HCC was 34% (95% CI, 1.3-6.3) and 17% (95% CI, 5.7-9.2) in genotype 3 and non-3 genotype groups, respectively (P = 0.002). In multivariate analysis, infection with a genotype 3 was independently associated with an increased risk of HCC occurrence [hazard ratio 3.54 (95% CI, 1.84-6.81), P = 0.0002], even after adjustment for prothrombin activity and alcohol abuse [3.58 (1.80-7.13); P = 0.003]. For patients with HCV cirrhosis and ongoing infection, infection with genotype 3 is independently associated with an increased risk of HCC development.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21914071     DOI: 10.1111/j.1365-2893.2011.01441.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  62 in total

Review 1.  Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.

Authors:  Steven W Johnson; Dorothea K Thompson; Brianne Raccor
Journal:  Curr Infect Dis Rep       Date:  2017-06       Impact factor: 3.725

Review 2.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 3.  Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Authors:  Austin Chan; Keyur Patel; Susanna Naggie
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

Review 4.  Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.

Authors:  Paola Dongiovanni; Stefano Romeo; Luca Valenti
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 5.  Hepatitis C genotype 3 disease.

Authors:  Sarah Kattakuzhy; Rachel Levy; Elana Rosenthal; Lydia Tang; Eleanor Wilson; Shyam Kottilil
Journal:  Hepatol Int       Date:  2016-06-21       Impact factor: 6.047

6.  Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.

Authors:  Necati Örmeci; Murat Taner Gülşen; Orhan Sezgin; Sevda Aghayeva; Mehmet Demir; Iftihar Köksal; Rahmet Güner; Elife Erarslan; Özgün Ömer Asiller; Ayhan Balkan; Serkan Yaraş; Aysun Çalışkan Kartal
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

7.  Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

Authors:  Luis Margusino-Framiñán; Purificación Cid-Silva; Sandra Rotea-Salvo; Álvaro Mena-de-Cea; Francisco Suárez-López; Pilar Vázquez-Rodríguez; Manuel Delgado-Blanco; Ana Isabel Sanclaudio-Luhia; Isabel Martín-Herranz; Ángeles Castro-Iglesias
Journal:  Eur J Hosp Pharm       Date:  2020-02-07

Review 8.  Hepatitis C virus infection: Are there still specific problems with genotype 3?

Authors:  Claire Gondeau; Georges Philippe Pageaux; Dominique Larrey
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 9.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Shiv K Sarin; Radha K Dhiman; Rakesh Aggarwal; Shivaram P Singh; Deepak Amarapurkar; Anil Arora; Mohinish Chhabra; Kamal Chetri; Gourdas Choudhuri; Vinod K Dixit; Ajay Duseja; Ajay K Jain; Dharmesh Kapoor; Premashis Kar; Abraham Koshy; Ashish Kumar; Kaushal Madan; Sri P Misra; Mohan V G Prasad; Aabha Nagral; Amarendra S Puri; R Jeyamani; Sanjiv Saigal; Samir Shah; Praveen K Sharma; Ajit Sood; Sandeep Thareja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2014-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.